SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
06 avr. 2022 07h00 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
05 avr. 2022 16h51 HE
|
SELLAS Life Sciences Group, Inc.
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial...
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
31 mars 2022 21h03 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
31 mars 2022 16h11 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
31 mars 2022 16h08 HE
|
SELLAS Life Sciences Group, Inc.
- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset - - Completion of Ongoing Phase 1 Trial in the United States/China Expected by Q4 2022 in Relapsed and/or...
SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer
14 mars 2022 07h00 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel...
SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation
28 févr. 2022 09h00 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel...
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
01 févr. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final...
SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China
26 janv. 2022 20h00 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel...
SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer
05 janv. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel...